Author

Darlene M. Rozewski

Observed names: D ROZEWSKI, D. M. Rozewski, Darlene Rozewski

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University

Observed institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Indiana University

OpenAlex ID: A5033650261

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo

2009 · David M. Lucas, Ryan B. Edwards, et al. · Blood · 171

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

2008 · Mitch A. Phelps, Thomas S. Lin, et al. · Blood · 155

Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias

2010 · William Blum, Rebecca B. Klisovic, et al. · Journal of Clinical Oncology · 87

Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein

2011 · Craig C. Hofmeister, Xiaoxia Yang, et al. · Journal of Clinical Oncology · 85

Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias

2010 · W. Blum, M. A. Phelps, et al. · Haematologica · 61

A novel liposomal formulation of flavopiridol

2008 · X YANG, X ZHAO, et al. · International Journal of Pharmaceutics · 50

Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice

2012 · Darlene M. Rozewski, Sarah E. M. Herman, et al. · The AAPS Journal · 35

Differential effects of IL-2 and IL-21 on expansion of the CD4+CD25+Foxp3+T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia

2010 · Aruna Gowda, Asha Ramanunni, et al. · mAbs · 25

Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue

2013 · Yao Jiang, Jiang Wang, et al. · Journal of Pharmaceutical and Biomedical Analysis · 24

Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule

2008 · Mitch A. Phelps, Darlene M. Rozewski, et al. · Journal of Chromatography B · 17

R educed occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

2015 · Kami Maddocks, Lai Wei, et al. · American Journal of Hematology · 16

A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia

2014 · Kami Maddocks, Amy S. Ruppert, et al. · Leukemia Research · 11

Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice

2019 · Jim H. Hughes, Richard N. Upton, et al. · Cancer Chemotherapy and Pharmacology · 9

Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial,

2011 · Kristie A. Blum, Lai Wei, et al. · Blood · 4

Pharmacokinetics and P-glycoprotein-Mediated Transport of the Leading IMiDs in Mice

2012 · Darlene M. Rozewski · OhioLink ETD Center (Ohio Library and Information Network)

Abstract 5473: The contribution of P-glycoprotein to clinical pharmacokinetic interactions between lenalidomide and temsirolimus

2011 · Xiaoxia Yang, Hofmeister C. Craig, et al. · Cancer Research

Works count: 16

Citation count: 750

H-index: 11

I10-index: 12